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INTRODUCTION 
Cognitive impairment and dementia associated with Parkinson’s disease (PD) are common and 
frequently devastating problems that represent major management challenges.  Although figures 
vary depending upon populations assessed, test batteries applied and definitions used, between one 
fifth and one third of newly diagnosed people with PD will have some form of cognitive impairment 
at the time of presentation (5, 21).  The pattern of dysfunction is heterogeneous and the prognostic 
implications for one type of cognitive impairment over another are yet to be established.  
Additionally, clinically significant neuropsychiatric symptoms occur in 27% of incident PD cases, 
compared with only 3% in age-matched controls.  Depression, apathy, sleep disturbance and anxiety 
are the most frequently reported symptoms in these patients (4). 
Longitudinal studies suggest that 10% of patients with PD develop dementia annually, a rate four to 
six times greater to that found in age-matched controls (2).  Ultimately, up to 80% of people with PD 
develop dementia (1, 30).  Dementia associated with PD (PD-D) is associated with increased 
mortality, earlier institutionalisation and reduced quality of life for both patient and carer. 
Dementia that occurs earlier in the course of PD may share greater pathological characteristics with 
dementia with Lewy bodies (DLB), with greater cortical Lewy body loads and amyloid plaque burden 
(29).   Patients who survive for longer before the onset of dementia tend to have greater subcortical 
pathology, with Lewy body distribution conforming to the Braak staging of PD.  They have less 
neocortical pathology and greater evidence of cortical cholinergic deficits (9, 29).  
Taken together, these clinical and pathological observations have major implications for the 
effective management of PD-D, and emphasise the need for early intervention, better 
characterisation of the clinico-pathological phenotypes and consideration of a variety of treatment 
approaches, including both amyloid and synuclein protein “busting” approaches.  This brief review 
will consider current treatment approaches to cognitive impairment in PD. It will also briefly 
consider future strategies. 
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EARLY COGNITIVE IMPAIRMENT IN PD: TO TREAT OR NOT TO TREAT?  
As described above, “mild cognitive impairment” is a common finding in newly diagnosed PD.  This 
has been defined on the basis of formal neuropsychometric testing.  What is not known is how these 
deficits contribute towards disability or indeed whether they progress in a predictable way towards 
PD-D.   The latter almost certainly depends upon the underlying pathophysiological substrate, with 
certain forms of cognitive impairment having more sinister portent, and higher likelihood of 
conversion to PD-D (67).  Were this to be confirmed, then such cases would clearly be the target for 
aggressive disease modifying approaches, in an effort to delay the inevitable cognitive decline and 
conversion to PD-D. 
There has been considerable controversy whether dopaminergic drugs used to treat the motor 
symptoms of PD may have beneficial or indeed deleterious effects upon cognition in early PD.  A two 
year longitudinal, parallel, randomised open study of L-dopa or pergolide treatment in newly 
diagnosed PD suggested that both drugs were associated with incomplete but long-lasting 
improvements in several cognitive tasks, which declined thereafter (33).  Moreover, no significant 
changes were noted on attentional, short-term memory and Stroop tests during the study in either 
group.   More recently, the concept of contrasting effects of L-dopa reflecting the spatio-temporal 
progression of dopamine depletion within the striatum has been proposed (14). This persuasive 
hypothesis suggests that L-dopa may improve cognitive functions mediated by areas that are initially 
hypo-dopaminergic, such as the dorsal striatum, whereas L-dopa replacement in areas that are 
initially relatively preserved, notably the ventral striatum, may impair cognitive functions via a 
relative “over-dosing”.  Overall, therefore, dopaminergic drugs may have some benefits upon mild 
cognitive dysfunction in early PD, but these effects are partial, and unlikely to be of major clinical 
relevance. 
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A recent open-label study examined the use of atomoxetine, a norepinephrine reuptake inhibitor, in 
the treatment of disabling executive dysfunction associated with non-demented PD (42).  
Atomoxetine was associated with improvements in all three primary outcome measures, which 
included the clinician’s global impression of change and behavioural measures of executive 
dysfunction.  Adverse effects included sleep, gastrointestinal disturbance and, in one subject, 
hypomania.  This preliminary study offers a novel neurochemical approach to the management of 
cognitive dysfunction in PD, although further randomised, placebo controlled studies are necessary 
to better establish both the efficacy and tolerability of atomoxetine. 
Glutamatergic agents have also been considered as potential disease-modifying agents for delaying 
progression to PD-D, as well as for symptomatic benefits for early cognitive dysfunction.  Thus, 
Inzelberg and colleagues reported that use of amantadine, a drug with N-methyl-D-aspartate 
(NMDA) receptor blocking properties, was associated with slower mental decline, delaying the onset 
of dementia, and attenuating its severity (32).  Although an intriguing result, this study was non-
randomised and potentially subject to several inherent biases.   Safinamide, a unique molecule with 
both dopaminergic and glutamatergic properties, is currently undergoing evaluation for its effects on 
motor function in early and late PD (49).  Preliminary data also suggests that safinamide may have 
some benefits upon executive dysfunction in early PD, and this is currently being pursued as part of 
the drug development programme.  
In the face of profound cholinergic deficits in both early and advanced PD, with and without 
dementia (59), one randomised study recently examined the use of the cholinesterase inhibitor 
galantamine to improve cognition in non-demented PD subjects (28).   Disappointingly, the drug did 
not lead to any improvement in attention/executive function, memory or visuospatial performance.  
Furthermore, the drug was poorly tolerated, mainly due to gastrointestinal side effects and self-
reported worsening of parkinsonian symptoms. 
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THE MANAGEMENT OF ESTABLISHED DEMENTIA  
1. General Principles 
The onset of functionally disabling cognitive impairment may be both slow and insidious in a patient 
who the physician has been following up for several years for the management of motor problems.  
Significant cognitive dysfunction may be denied by the patient, or covered over by the carer (e.g. 
“we all get a bit forgetful when we get older – I’m no different”).  If in any doubt, a thorough clinic 
re-assessment, including recording cognitive and neuropsychiatric function, should be undertaken, 
with reference to recently described Movement Disorder Society Task Force Criteria for the 
diagnosis of PD-D (16, 19).  The insensitivity of the Mini-Mental Status Examination (MMSE) to 
detect impairments in PD-D has been well highlighted and this scale should not be relied upon to 
confirm or refute the diagnosis.  Some measure of fluctuating attention should also be attempted, 
since this can have a major impact upon activities of daily living (12).  
In the course of assessment, treatable problems should be excluded.  These include significant 
dementia, and ruling out the unlikely possibility of an underlying metabolic disorder, such as 
hypothyroidism.  There should be a high index of suspicion for chronic subdural haematoma, 
particularly if the clinical course is atypical, as this may be “silent”, and often no clear history is 
obtained for antecedent head injury.   Urinary tract, and other infections, should be considered and 
actively treated. 
The rationalisation of anti-parkinsonian and other medication may have a beneficial impact upon 
psychotic symptoms in PD, and can preclude the need for anti-psychotic drugs in up to 60%, at least 
in the short-term (64).   Typical offending agents include anticholinergics (now more likely to be 
prescribed for urinary symptoms), amantadine, selegiline and dopamine agonists.  If necessary there 
should be a graded withdrawal of these drugs, with the patient reverting to L-dopa monotherapy, in 
the lowest possible dose. 
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Demented PD patients are more likely to fall than non-demented patients, and impaired attention is 
independently predictive of falls (8).  Appropriate measures, including the use of hip protectors, an 
assessment with bone densitometry and prescription of “bone protection” agents if necessary and 
an occupational therapy home assessment should all be routinely considered.   If still driving, the 
patient should be asked to inform the relevant authority, and warned that their license may well be 
revoked.  
Finally, it should be remembered that medical decision making capacity is impaired in PD-D, and that 
significant impairments may also occur in cognitively impaired PD patients without dementia (43).  
The latter particularly applies to understanding treatment consent, with an appreciation of 
treatment choices and risks versus benefits. 
 
2. Atypical Antipsychotic Agents 
Using an administrative health care database in Ontario, Canada, Marras and colleagues determined 
that the cumulative probability of a person with PD,  aged 66 or older, requiring an antipsychotic 
drug was 35% at 7 years (41).  The use of “typical” (that is, drugs with high dopamine D2 receptor 
antagonism) fell from 56% of prescriptions in 1998 to 9% in 2002.  These figures imply that a large 
number of older people are prescribed antipsychotics relatively early in their disease duration.  
Intriguingly, an observational prospective study has suggested that the early of use an atypical 
antipsychotic drug in people with PD and mild hallucinations with retained insight might reduce the 
risk of deterioration to a state of delusions or hallucinations without insight (27).   In the absence of 
a randomised trial these results are difficult to explain, although at least one possibility is that the 
drugs in some way are able to modify the natural history of psychosis in PD. 
The majority of trials of antipsychotics in PD have either excluded PD-D, or at best included a 
relatively small number of subjects, so the efficacy of these drugs in the demented case with active 
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psychosis is not clearly established.  In non-demented PD patients, the use of risperidone, 
olanzepine and aripiprazole has been associated with unacceptable worsening of extrapyramidal 
symptoms and signs, so these agents are best avoided (23, 25).  Two randomised controlled trials 
have demonstrated that clozapine is efficacious in non-demented PD patients with psychosis (51, 
62), although the need for regular blood monitoring makes this a difficult drug to use.  Quetiapine 
has not been shown to be effective in two randomised placebo-controlled trials in treating PD-
related psychosis (48, 54), although a hypnotic effect and ease of use continue to make this agent a 
first choice in most centres.   In the study of Rabey and colleagues 29 of the 58 study participants 
had dementia (54). There were no significant differences in treatment response between demented 
and non-demented patients.   Data are conflicting for whether the use of quetiapine in PD-D is 
associated with worsening of parkinsonism: Two studies have suggested that this is the case (20, 56), 
while two others did not report any obvious deterioration (34, 54). 
Ziprasidone can potentially prolong the Q-T interval. Studies of this agent in PD have been limited to 
open-label trials and case reports and the results are highly variable (25).  Ziprasidone may also be 
administered parenterally.   
A phase II double-blind, placebo-controlled study of pimavanserin, a 5-HT2A inverse 
agonist/antagonist in 60 people with treatment-induced psychosis reported that the drug did not 
worsen motor symptoms (the primary end-point) and also reduced psychosis, as measured by 
percent change from baseline on the Scale for Assessment of Positive Symptoms (SAPS) (24).  A 
recent phase III multi-centre, double-blind, placebo-controlled study with this agent did not, 
however, meet its primary endpoint of antipsychotic efficacy as measured using the SAPS.  A total of 
298 patients were enrolled in the trial and randomized to one of three study arms, including two 
different doses of pimavanserin (10 mg or 40 mg) and placebo.  Patients showed marked 
improvements in the SAPS scores across all study arms.  At day 42, mean reductions in SAPS scores 
were 5.9 points in the placebo arm, 5.8 points in the 10 mg pimavanserin arm, and 6.7 points in the 
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40 mg pimavanserin arm.  Statistical significance was not achieved in either pimavanserin arm, 
primarily due to the larger than expected improvement in placebo-treated patients.  Pimavanserin 
met the key secondary endpoint of not worsening motor function and was safe and well tolerated, 
with the frequency of adverse events generally similar in the pimavanserin and placebo arms 
(http://www.acadia-pharm.com).  The patients enrolled in this study were non-demented. 
It is therefore difficult to recommend an anti-psychotic agent for use in PD-D on evidence currently 
available.  If required, low dose quetiapine (25mg per day, escalating very slowly to 100-150mg per 
day) would be our usual agent of choice.  In the person with PD-D, however, cholinesterase 
inhibitors may have useful anti-psychotic potential and can obviate the need for additional atypical 
anti-psychotics. 
 
3. Cholinesterase Inhibitors 
Multiple convergent lines of evidence from clinical, neuroimaging, pathological and neurochemical 
studies indicate a profound loss of cholinergic neurotransmission in PDD, in excess of that found in 
Alzheimer's disease (AD) (11, 22, 65).  This loss underpins several core features of PD-D.  
Cholinesterase inhibitor drugs (ChEIs) act to improve cholinergically-mediated cognitive and 
neuropsychiatric symptoms in PDD by reducing enzymatic breakdown of acetylcholine.  There is 
therefore a sound scientific rationale for the use of these agents in the symptomatic management of 
PD-D.  Using functional imaging ChEIs have been associated with increased regional cerebral glucose 
metabolism and blood flow in patients with PD-D (31, 35).    
Open-label trials have suggested that galantamine may be efficacious in PD-D (6, 38), but in the 
absence of randomized studies it is not possible to draw any firm conclusion.  Just two adequately 
sized randomized controlled trials have been performed for the use of ChEIs in PD-D and only one of 
these (EXPRESS study of rivastigmine, n=541) has fully reported (18), with the other (EDON study of 
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donepezil, n = 549), published in abstract form (17).  The other three randomized trials have been 
very small, recruiting a total of 52 patients between them (7, 36, 55).  Both the EXPRESS and EDON 
studies recruited PD patients with mild to moderate dementia, with treatment durations of 24 
weeks.  EXPRESS study participants were also offered the chance to enter an active treatment 
extension phase over an additional 24 weeks.  Using the cognitive subscale of the Alzheimer's 
Disease Assessment Scale (ADAS-cog, range 0-70 points max), modest but statistically significant 
benefits were noted in both studies at 24 weeks in the ChEI group (2.8 points improvement in active 
vs. placebo groups in EXPRESS and 3.4 points improvement in active vs. placebo groups in EDON).  
Significant improvements were also noted in the EXPRESS study in several secondary outcome 
measures, including activities of daily living and burden of neuropsychiatric symptoms. 73% of those 
assigned to rivastigmine completed treatment, compared to 82% of those allocated to placebo; the 
main reason for premature withdrawal was adverse events. 93% of patients, receiving rivastigmine 
provided follow-up data on at least one occasion, contributing to the efficacy analysis compared 
with 92% in the placebo group. The study could be criticized, however, for the use of ‘last 
observation carried forward’ as the means of imputation of missing data for those lost to follow-up 
prior to 24 weeks. There were fewer deaths in the active treated group (4/362 versus 7/179, OR 
0.27, 95% CI 0.08 to 0.95, p = 0.04).  Patients receiving rivastigmine in the active treatment extension 
study continued to derive a small improvement from the drug at 48 weeks (53).  A subsequent 
report derived from the EXPRESS study assessments highlighted the benefits of rivastigmine 
compared to placebo at 24 weeks on computerized measures of attention, including sustained 
attention (66). 
A problem with both the EXPRESS and EDON RCTs is that they used the generic Diagnostic Statistical 
Manual IV (DSM-IV) criteria to define dementia in PD, and graded severity according to MMSE score. 
Neither the DSM-IV criteria nor the MMSE capture the cognitive profile of PD-D, potentially biasing 
the sample to patients with a more "Alzheimer-type" presentation, and excluding those with greater 
executive dysfunction who arguably may have benefited more from the ChEI intervention.  It is 
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possible for a PD patient to have dementia but a "normal" MMSE score, yet such patients would 
have been excluded from the EXPRESS and EDON studies.  Furthermore, the ADAS-cog as a primary 
outcome measure is arguably better suited to the cognitive dysfunction observed in AD patients and 
is not ideally tailored to measure treatment effects in PD-D.  In particular, it is relatively insensitive 
to the prominent and early dysexecutive problems that characterize PD-D. No quality of life, carer 
strain or health economic measures were reported in these studies.  
A Cochrane review (39) identified only one RCT, the aforementioned EXPRESS study (18), that 
fulfilled pre-specified inclusion criteria and concluded that rivastigmine appeared to improve 
cognition and activities of daily living in PD-D, resulting in clinically meaningful benefit in 15% of 
cases.  This review suggested that future trials in PD-D should involve other ChEIs, utilize analytic 
tools that limit any bias and also measure health economic factors.  Patient and carer quality of life 
assessments were also recommended as outcome measures.   
In 2006 the American Academy of Neurology Practice Parameter document suggested that donepezil 
or rivastigmine should be considered for the treatment of PD-D (46).  In the same year, the National 
Institute for Clinical Excellence in the UK recognized that while ChEIs have been used successfully in 
individual people with PD-D, further research was recommended to identify those patients who will 
benefit from this treatment (63).     
A 76-week prospective, multi-centre, open-label trial is ongoing to evaluate the long-term effect of 
rivastigmine capsule and transdermal patch on worsening of motor symptoms in patients with mild 
to moderately severe PD-D (www.clinicaltrials.gov).  The rivastigmine patch, which may be 
associated with superior tolerability over the capsule preparation, is already licensed for use in 
Alzheimer’s disease in several countries. 
Although some patients report an increase in tremor on ChEI, this is an uncommon reason for 
discontinuation of the drug (18) and, objectively, motor kinematic measures are unaffected (44). 
More recently, there have been safety concerns raised in a large population-based study of a 
heterogeneous group of patients prescribed ChEIs for a range of dementias (the majority having 
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Alzheimer’s disease) (26).  Compared with control subjects, the 19,803 community-dwelling older 
adults with dementia prescribed ChEIs had more frequent hospital visits for bradycardia (Hazard 
Ratio, HR, 1.69 with 95% confidence interval, CI, 1.32-2.15), permanent pacemaker insertion  (HR 
1.49; 95% CI 1.12-2.0) and hip fracture (1.18; 95% CI 1.04-1.34).  Although the hazard ratios were 
significant, the absolute number of events was small.   A previously published clinical protocol 
indicated that pre-treatment electrocardiograms and 24-hour cardiac monitoring were not justified 
(57) and that there were no high-risk groups for whom to target screening.  Nevertheless, the paper 
conceded that checking the patient’s pulse was important, and that detection of bradycardia (< 50 
beats per minute) before or during treatment should be investigated further and the patient 
monitored more frequently thereafter.     
The clinical to response to ChEIs is highly variable and attempts have been made to identify those 
patients likely to respond to the drugs.  A highly sensitive and specific predictor would have both 
clinical and economic benefits, as well as potentially informing regarding the underlying 
pathophysiology.  From a sub-analysis of the EXPRESS study, visual hallucinations appear to predict 
more rapid decline and possibly greater therapeutic benefit from rivastigmine treatment in PDD 
(13).  Neurophysiological  studies suggest that latency of the P3 event-related potential may predict 
response to donepezil (50), while short-latency afferent inhibition technique may be useful to 
monitor the efficacy of ChEI treatment (40).  A single nucleotide polymorphism in the cytochrome 
P450 CYP2D6 gene may influence the efficacy of donepezil in mild to moderate Alzheimer’s disease 
(52).  Patients with the” G” allele had a significantly higher risk of poor response to the ChEI (odds 
ratio 3.43; 95% CI 1.49-7.9) in this study.  The functional effect of this polymorphism on treatment 
response in PD-D has not yet been reported.   
Whilst debate continues regarding the relative efficacy for ChEIs in the treatment of PD-D, it would 
be prudent to withdraw the agents gradually, should it be decided that they are not beneficial in a 
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given patient.  Sudden ChEI withdrawal has been associated with acute cognitive and behavioural 
decline (45). 
 
4. Memantine 
Memantine is a dimethyl derivative of amantadine and possesses NMDA receptor blocking 
properties.  The drug modulates glutamatergic neuronal transmission and could potentially prevent 
the toxic effects of raised concentrations of glutamate.  Memantine has previously been shown to 
have clinical efficacy in Alzheimer’s disease and vascular dementia.  A small randomised controlled 
trial of this agent in PD-D showed that the drug was well tolerated, but due to the small numbers 
enrolled, only indirect evidence was gained for efficacy, in that more patients taking the active drug 
deteriorated at the end of the study compared with those allocated to placebo (37). 
A larger randomised trial of memantine in the Lewy body dementias (that is, patients with either PD-
D or DLB) enrolled 72 patients, 40 of whom had PD-D (3).  Concomitant stable prescription of a ChEI 
was permitted.  The clinical global impression of change was the primary outcome measure, and at 
24 weeks there was a significant difference between those taking memantine versus those taking 
placebo (mean difference 0.7; 95% CI 0.04-1.39; p=0.03) in favour of the NMDA antagonist.  With the 
exception of the quick test of cognition, there were no significant differences detected in any of the 
secondary outcome measures.  78% of the 72 participants completed the study, with a similar 
proportion of withdrawals occurring in the two groups.  A further Lundbeck A/S sponsored 
randomised 6 month study of memantine in the Lewy body dementias has completed 
(www.clinicaltrials.gov ).  In this study, participants were not permitted to take ChEI.   The results are 
eagerly awaited, as there is still uncertainty regarding memantine’s efficacy in PD-D, and whether it 
should be prescribed with, or instead of, a ChEI.   Intriguingly, one study has reported that donepezil 
can markedly potentiate memantine neurotoxicity in the adult rat brain, possibly via disinhibition-
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mediated increased excitatory tone (15).   The implications for this finding in humans treated with 
both memantine and a ChEI are uncertain at present, and further work is clearly required to clarify 
the issue.     
 
FUTURE DIRECTIONS 
A range of non-pharmacological approaches should be explored in the management of cognitive 
impairment associated with PD.  For example, there is increasing interest in the potential for 
exercise to improve cognitive function.  A recent small study has reported that a multimodal exercise 
programme can improve executive function in PD (61).  “Medical foods” are also attracting interest, 
with preclinical animal studies suggesting that a combination of nutrients may increase synapse 
formation and reduce beta-amyloid production.  Randomised controlled trials are underway in 
Alzheimer’s disease, after encouraging preliminary results (58). 
Multifunctional drugs may offer hope in the dual management of motor and cognitive aspects of PD.  
Safinamide, mentioned above, would be one example of such a drug.  Other potential agents in 
development include ladostigil (68) and adenosine receptor antagonists (60).  
If synuclein-related pathology underpins the onset of dementia in people with PD, then the 
development of anti-synuclein protein aggregating (so-called “synuclein busting”) agents could 
represent a significant development in delaying or averting the onset of cognitive decline, 
particularly since they could be introduced at a relatively early stage in non-demented PD patients.   
Such agents may end up coming from a variety of backgrounds and therapeutic mechanisms. The 
cholesterol-lowering compound methyl-β-cyclodextrin, for example, has been shown to reduce 
neuronal α-synuclein accumulation in mice, via putative lipid-synuclein interaction (10).   
From in vivo imaging and pathological studies, however, it seems probable that the pathological 
basis for PD-D is heterogeneous, with Alzheimer-type lesions (particularly amyloid plaques) playing 
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an important role.  Further work is therefore required to better characterise the clinical variability of 
early cognitive impairment associated with PD as well as PD-D and how these phenotypes relate to 
existing biomarkers such as 
11
C-PIB positron emission tomography and cerebrospinal protein analysis 
(i.e. synuclein, amyloid and tau concentrations).  In doing so, this could provide an opportunity to 
therapeutically target the predominant protein aggregate(s) in an earlier window of opportunity (47) 
 
CONCLUSION 
This review has considered the management of the spectrum of cognitive dysfunction associated 
with PD.  Such dysfunction is now regarded as an integral and, as our patients survive for longer, an 
almost inevitable component of the disease.  The variability in onset and rate of cognitive decline, 
together with the heterogeneous clinical phenotype argues strongly for a multifactorial pathological 
basis for PD-D.   Symptomatic treatments can lead to gratifying benefits in established dementia, but 
more work is required to better evaluate the clinical relevance of such interventions, as well as their 
cost-effectiveness.  Not all PD-D patients improve with these treatments, and better predictors of 
response would be welcome.  Beyond neurotransmitter modulation, there is an urgent need for the 
development of disease modifying therapies that target the responsible pathological processes.  To 
maximise response, such therapies may well need to be individualised, and based upon results from 
imaging studies, cerebrospinal fluid analysis and other biomarkers.   
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